Vericel
Vericel markets three advanced cell therapy products in the U.S., including MACI for knee cartilage repair, Epicel for severe burns, and holds the North American rights to NexoBrid for eschar removal.
Products
Vericel specializes in three advanced cell therapy products in the U.S. These include MACI, Epicel, and NexoBrid. MACI is designed for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients and uses autologous cultured chondrocytes on a porcine collagen membrane. Epicel serves patients suffering from deep dermal or full thickness burns covering 30% or more of the total body surface area. Additionally, Vericel holds exclusive North American commercial rights to NexoBrid, a biological orphan product approved for eschar removal of severe thermal burns.
NexoBrid
Vericel holds an exclusive North American commercial license for NexoBrid. This biological orphan product is approved for the eschar removal of severe thermal burns. NexoBrid offers an enzymatic debridement option, which is crucial for the treatment of patients with severe burn injuries. By holding this exclusive license, Vericel ensures that advanced care is accessible within the North American market.
MACI
MACI is one of Vericel's key products, aimed at treating full-thickness cartilage defects in the knee. It utilizes autologous cultured chondrocytes that are expanded and placed on a porcine collagen membrane, offering a specialized solution for adult patients dealing with symptomatic cartilage problems. MACI is an example of Vericel's commitment to providing advanced cell therapy solutions for specific medical conditions.
Epicel
Epicel is a cultured epidermal autograft (CEA) provided by Vericel for patients with severe burn injuries. Specifically, it is used for individuals with deep dermal or full thickness burns that cover 30% or more of their total body surface area. Epicel represents a crucial treatment option for those requiring extensive skin regeneration, highlighting Vericel's focus on cell-based therapies for severe medical conditions.
Company Mission
Vericel is dedicated to advancing novel therapies through its current portfolio and ongoing business development efforts. The company is committed to providing specialized cell-based therapies that address severe medical conditions. By focusing on innovation and patient needs, Vericel aims to continue expanding its range of treatment options in the cell therapy market.